146 related articles for article (PubMed ID: 37524252)
1. Unraveling the molecular landscape: a comparative analysis of PI3K and MAPK signaling pathways in plasmablastic lymphoma and diffuse large B-cell lymphoma with therapeutic implications.
Mansoor A; Akhter A; Kamran H; Minoo P; Stewart D
Hum Pathol; 2023 Nov; 141():102-109. PubMed ID: 37524252
[TBL] [Abstract][Full Text] [Related]
2. Identification of Potential Therapeutic Targets for Plasmablastic Lymphoma Through Gene Expression Analysis: Insights into RAS and Wnt Signaling Pathways.
Mansoor A; Kamran H; Akhter A; Seno R; Torlakovic EE; Roshan TM; Shabani-Rad MT; Elyamany G; Minoo P; Stewart D
Mod Pathol; 2023 Aug; 36(8):100198. PubMed ID: 37105495
[TBL] [Abstract][Full Text] [Related]
3. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.
Witte HM; Künstner A; Hertel N; Bernd HW; Bernard V; Stölting S; Merz H; von Bubnoff N; Busch H; Feller AC; Gebauer N
Blood Adv; 2022 Jan; 6(2):637-651. PubMed ID: 34714908
[TBL] [Abstract][Full Text] [Related]
4. Exploration and analysis of differentially expressed genes in Epstein-Barr virus negative and positive plasmablastic lymphoma.
Liang Y; Wang H; Luo B
Clin Transl Oncol; 2023 Oct; 25(10):2884-2891. PubMed ID: 36991219
[TBL] [Abstract][Full Text] [Related]
5. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.
Ramis-Zaldivar JE; Gonzalez-Farre B; Nicolae A; Pack S; Clot G; Nadeu F; Mottok A; Horn H; Song JY; Fu K; Wright G; Gascoyne RD; Chan WC; Scott DW; Feldman AL; Valera A; Enjuanes A; Braziel RM; Smeland EB; Staudt LM; Rosenwald A; Rimsza LM; Ott G; Jaffe ES; Salaverria I; Campo E
Haematologica; 2021 Oct; 106(10):2682-2693. PubMed ID: 33951889
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic features and abnormal signaling pathways in plasmablastic lymphoma: a multicenter study in China.
Shi D; Gao L; Wan XC; Li J; Tian T; Hu J; Zhang QL; Su YF; Zeng YP; Hu ZJ; Yu BH; Li XQ; Wei P; Li JW; Zhou XY
BMC Med; 2022 Dec; 20(1):483. PubMed ID: 36522654
[TBL] [Abstract][Full Text] [Related]
7. Plasmablastic lymphoma: An update.
Bailly J; Jenkins N; Chetty D; Mohamed Z; Verburgh ER; Opie JJ
Int J Lab Hematol; 2022 Sep; 44 Suppl 1(Suppl 1):54-63. PubMed ID: 36074710
[TBL] [Abstract][Full Text] [Related]
8. Primary Gastric EBV-positive Diffuse Large B Cell Lymphoma (DLBCL) of the Elderly with Plasmablastic Differentiation.
Hu M; Trevino J; Yang L; Cao D; Liu X; Lai J
In Vivo; 2018; 32(2):413-417. PubMed ID: 29475930
[TBL] [Abstract][Full Text] [Related]
9. Rectal plasmablastic lymphoma in Ebstein Barr virus positive and human immunodeficiency virus negative subject after external radiation therapy for prostatic cancer.
Bricman L; Yengue P; Miscu C; Junius S; Waignein F; Vandenbulcke JM
Acta Gastroenterol Belg; 2021; 84(4):663-665. PubMed ID: 34965049
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways.
Kato H; Karube K; Yamamoto K; Takizawa J; Tsuzuki S; Yatabe Y; Kanda T; Katayama M; Ozawa Y; Ishitsuka K; Okamoto M; Kinoshita T; Ohshima K; Nakamura S; Morishima Y; Seto M
Cancer Sci; 2014 May; 105(5):537-44. PubMed ID: 24581222
[TBL] [Abstract][Full Text] [Related]
11. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.
Zhao CX; Yan ZX; Wen JJ; Fu D; Xu PP; Wang L; Cheng S; Hu JD; Zhao WL
Mol Cancer; 2021 Dec; 20(1):153. PubMed ID: 34852843
[TBL] [Abstract][Full Text] [Related]
12. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.
Pfeifer M; Grau M; Lenze D; Wenzel SS; Wolf A; Wollert-Wulf B; Dietze K; Nogai H; Storek B; Madle H; Dörken B; Janz M; Dirnhofer S; Lenz P; Hummel M; Tzankov A; Lenz G
Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12420-5. PubMed ID: 23840064
[TBL] [Abstract][Full Text] [Related]
13. Plasmablastic lymphoma: current knowledge and future directions.
Li JW; Peng HL; Zhou XY; Wang JJ
Front Immunol; 2024; 15():1354604. PubMed ID: 38415257
[TBL] [Abstract][Full Text] [Related]
14. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management.
Malpica L; Marques-Piubelli ML; Beltran BE; Chavez JC; Miranda RN; Castillo JJ
Am J Hematol; 2022 Jul; 97(7):951-965. PubMed ID: 35472248
[TBL] [Abstract][Full Text] [Related]
15. Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients.
Laurent C; Fabiani B; Do C; Tchernonog E; Cartron G; Gravelle P; Amara N; Malot S; Palisoc MM; Copie-Bergman C; Glehen AT; Copin MC; Brousset P; Pittaluga S; Jaffe ES; Coppo P
Haematologica; 2016 Aug; 101(8):976-84. PubMed ID: 27175027
[TBL] [Abstract][Full Text] [Related]
16. Loss of B-cell receptor expression defines a subset of diffuse large B-cell lymphoma characterized by silent BCR/PI3K/AKT signaling and a germinal center phenotype displaying low-risk clinicopathologic features.
Wang WG; Cui WL; Wang L; Zhu F; Wan XC; Ping B; Zhou XY; Li XQ
Am J Surg Pathol; 2015 Jul; 39(7):902-11. PubMed ID: 25970684
[TBL] [Abstract][Full Text] [Related]
17. Plasmablastic lymphoma: from genetics to treatment.
Frontzek F; Hailfinger S; Lenz G
Leuk Lymphoma; 2023 Apr; 64(4):799-807. PubMed ID: 36577021
[TBL] [Abstract][Full Text] [Related]
18. Molecular complexity of diffuse large B-cell lymphoma: a molecular perspective and therapeutic implications.
Almasmoum HA
J Appl Genet; 2024 Feb; 65(1):57-72. PubMed ID: 38001281
[TBL] [Abstract][Full Text] [Related]
19. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
Li J; Qian C; Zhou Q; Li J; Li K; Yi P
Biochem Biophys Res Commun; 2017 Sep; 491(4):939-945. PubMed ID: 28756223
[TBL] [Abstract][Full Text] [Related]
20. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
